Related Experiment Video

Updated: Aug 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Pleiotropic effects of statins]

P E Westerweel1, M C Verhaar, T J Rabelink

  • 1Universitaire Medisch Centrum Utrecht, divisie Inwendige Geneeskunde en Dermatologie, afd. Vasculaire Geneeskunde, Utrecht.

Nederlands Tijdschrift Voor Geneeskunde
|August 26, 2004
PubMed

Insights

Statins effectively lower cardiovascular disease risk by reducing cholesterol. Beyond cholesterol, statins offer additional lipid-independent benefits, positively impacting atherosclerosis progression and endothelial function.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Cardiovascular disease remains a leading cause of morbidity and mortality.
  • Statins are primary agents for managing dyslipidemia and reducing cardiovascular risk.
  • Clinical trials predominantly focus on high-risk populations and late-stage atherosclerosis.

Purpose:

  • To elucidate the lipid-independent, or pleiotropic, effects of statins.
  • To explore how these effects influence the early stages of atherosclerosis.
  • To assess the clinical relevance of pleiotropic effects in cardiovascular risk reduction.

Summary:

  • Statins significantly reduce cardiovascular morbidity and mortality, primarily through cholesterol reduction.
  • Emerging evidence highlights statins' lipid-independent effects on atherosclerosis pathogenesis, including improved endothelial function and reduced inflammation.
  • These pleiotropic actions may contribute to risk reduction, particularly in high-risk patients and long-term prevention strategies.

Impact:

  • Recognizing statins' pleiotropic effects can refine therapeutic strategies for cardiovascular disease prevention.
  • Understanding these mechanisms may lead to novel therapeutic targets for atherosclerosis.
  • These findings emphasize the multifaceted benefits of statins beyond lipid-lowering in clinical practice.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...